Synerlab acquires Lyofal and IDD-Tech Orleans with the support of AXA Private Equity
Synerlab, a French pharmaceutical contract manufacturing firm, and AXA Private Equity have acquired Lyofal and IDD-Tech Orleans.
Lyofal, a company founded and managed by Jean-Luc Allemand, specialises in custom-lyophilisation (freeze-drying) while IDD-Tech Orleans specialises in the development of solid dosage forms.
With these acquisitions, Synerlab reinforces its leading market position and becomes a company with five sites, employing 700 people, and a turnover of EUR85m.
Lyofal’s longstanding expertise and excellent facilities will allow the Synerlab Group to extend its range of products and enter the attractive and growing lyophilization market. Synerlab will also benefit from Lyofal’s strong client portfolio, which ranges from large pharmaceutical to small biotechnology companies. The completion of the transaction remains subject to approval.
IDD-Tech Orleans, which now becomes Synerlab Developpement, has significant expertise in pharmaceutical solid dose formulation and analytical drug development up to pilot batch production scale. Its acquisition will allow Synerlab to offer its clients a full range of services from the initial drug development phase to industrial scale production. With the support of AXA Private Equity, Synerlab retains all IDD-Tech Orleans’ staff (20 employees) and will provide the company with the necessary resources to further its development and create a number of new jobs within the next two years.
Jean-François Loumeau, president of Synerlab, says: “These two acquisitions are perfect add-ons to our current manufacturing activities and are very much in line with our development strategy, which consists in developing our range of services to complement our core business.”
François Jerphagnon, managing director small market enterprise capital at AXA Private Equity, says: “With these acquisitions, Synerlab reinforces its leading position within the contract manufacturing market. AXA Private Equity’s commitment alongside the management team over the last five years, including the closing of three build-up acquisitions, is a good example of how we bring value to our portfolio companies.”
- By Category
- News from other sites
- Special Reports
- Partner events